Note 4 - Commitments (Details Textual) - USD ($) |
3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Mar. 31, 2026 |
Apr. 30, 2020 |
Dec. 31, 2016 |
|
| The Constructs [Member] | |||||||
| Maximum Contingent Obligation | $ 356,000,000 | ||||||
| Payments for Milestone, Royalty and Sublicensing | $ 0 | $ 0 | $ 0 | $ 0 | |||
| The Constructs [Member] | Drug Substance [Member] | |||||||
| Purchase Obligation | $ 5,000,000 | ||||||
| Payments to Suppliers | 0 | 0 | 0 | 0 | |||
| License Agreement Related to Pharmaceutical Products [Member] | |||||||
| Maximum Contingent Obligation | $ 18,400,000 | ||||||
| Finite-Lived License Agreements, Gross | $ 0 | ||||||
| Payments for Licensing and Royalties | 0 | $ 0 | 0 | $ 0 | |||
| License Agreement to Acquire Global Rights of Pharmaceutical Product [Member] | |||||||
| Maximum Contingent Obligation | $ 68,900,000 | ||||||
| Milestone Expense | $ 25,000 | $ 75,000 | |||||